A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
Conditions: Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms; HER2 Positive Breast Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms

Interventions: Drug: disitamab vedotin; Drug: tucatinib

Sponsors: Seagen Inc.; RemeGen Co., Ltd.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 10, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments